Lysosomal Acid Lipase Deficiency Treatment Market Size, Share & Trends Analysis Report By Treatment, By Indication (Wolman Disease, Cholesteryl Ester Storage Disease), And Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Report Scope
                 1.1 Indication Scope
                 1.2 Treatment Scope
                 1.3 Country Scope
                 1.4 Estimates and Forecast Timeline
Chapter 2 Methodology
                 2.1 Research Methodology
                     2.1.1 Information procurement
                 2.2 Information or Data Analysis
                 2.3 Market Formulation & Validation
                 2.4 List of Sources
                 2.5 List of Abbreviations
Chapter 3 Executive Summary
Chapter 4 Disease Primer and Epidemiology
                 4.1 Disease Primer
                     4.1.1 Stages and symptoms
                     4.1.2 Types
                         4.1.2.1 Wolman Disease
                         4.1.2.2 Cholesteryl Ester Storage Disease
                     4.1.3 Causes
                     4.1.4 Symptoms
                 4.2 Epidemiology
                     4.2.1 EPIDEMIOLOGICAL Forecast FOR LAL - D FOR Seven Major Markets (U.S., Japan, EU5)
Chapter 5 Global LAL - D Treatment Market Overview
                 5.1 Introduction and Market Overview
                 5.2 Market, by Treatment
                     5.2.1 Enzyme Replacement Therapy
                     5.2.2 Lipid Modifying Agents (Statins)
                     5.2.3 Surgery
                     5.2.4 Supportive Care
                 5.3 Market, by Indication
                     5.3.1 Wolman Disease
                     5.3.2 Cholesteryl Ester Storage Disease
                 5.4 Market Size and Forecast by Country (2017 - 2025)
                     5.4.1 Sales Performance by geographic markets, in $ million, 2017 - 2025
                     5.4.2 U.S.
                     5.4.3 Japan
                     5.4.4 U.K.
                     5.4.5 Germany
                     5.4.6 France
                     5.4.7 Spain
                     5.4.8 Italy
                 5.5 Market Share Distribution, by Company (2017 - 2025)
                 5.6 Market Dynamics and Brand Strategies
                 5.7 Patent Expiry Schedule
                 5.8 Lysosomal Acid Lipase Deficiency Market: Drivers and Restraints
                     5.8.1 Market Drivers and trends
                     5.8.2 Market Restraints
                 5.9 M & A, Deal Landscape (2014 - 2018 YTD)
                     5.9.1 Mergers & Acquisitions
                     5.9.2 Deals landscape
                 5.10 Pricing & Reimbursement
                 5.11 SWOT
Chapter 6 Company Profiles
                 6.1 Alexion Pharmaceuticals
                     6.1.1 Company Overview
                     6.1.2 Current Product Portfolio
                     6.1.3 Product Forecast Sales up to 2025
                     6.1.4 Strategic Initiatives
                         6.1.4.1 Key Company News Flow
                         6.1.4.2 Catalysts & events Calendar
                     6.1.5 SWOT
Chapter 7 Market Outlook
                 7.1 Winners and Losers
                     7.1.1 Winners
                     7.1.2 Losers
                 7.2 Emerging Companies/ New Technology Platforms
                 7.3 What the Future Holds

List of Tables

Table 1 List of Abbreviation
Table 2 Forecast Lysosomal Acid Lipase Deficiency (LAL - D) Prevalence, 2017 - 2025
Table 3 Forecast Lysosomal Acid Lipase Deficiency (LAL - D) Incidence, 2017 - 2025
Table 4 Sales by Indication, in $ Million, 2017 - 2025
Table 5 Sales by Treatment, in $ Million, 2017 - 2025
Table 6 Sales Performance by Geographic Markets, in $ Million
Table 7 LAL - D Drugs Patent Expiry Schedule
Table 8 Annual Cost Associated with LAL - D Treatment, by Country ($ Million)
Table 9 Pricing of Currently Available Treatment for LAL - D
Table 10 Alexion Pharmaceuticals Product Forecast Sales (2017 - 2025)
Table 11 Product Profile: Kanuma (sebelipase alfa)
Table 12 Alexion Pharma Product Forecast Sales (2017 - 2025)
Table 13 Kanuma Phase III Study

List of Figures

Fig. 1 Stages and Symptoms of Migraine
Fig. 2 LAL - D Types
Fig. 3 Global LAL - D Market Share, by Treatment (2017 - 2025)
Fig. 4 Market Segmentation and Scope
Fig. 5 LAL - D Market Share, by Indication (2017 - 2025)
Fig. 6 LAL - D Treatment Market Share, by Country (2017 & 2025)
Fig. 7 U.S. LAL - D Treatment Market, $ Million (2017 - 2025)
Fig. 8 Japan LAL - D Treatment Treatment Market, $ Million (2017 - 2025)
Fig. 9 U.K. LAL - D Treatment Market, $ Million (2017 - 2025)
Fig. 10 Germany LAL - D Treatment Market, $ Million (2017 - 2025)
Fig. 11 France LAL - D Treatment Market, $ Million (2017 - 2025)
Fig. 12 Spain LAL - D Treatment Market, $ Million (2017 - 2025)
Fig. 13 Italy LAL - D Treatment Market, $ Million (2017 - 2025)
Fig. 14 LAL - D Market Shares Distribution, by Company (2017 & 2025)
Fig. 15 LAL - D Treatment Market Sector SWOT
Fig. 16 Alexion Pharmaceuticals LAL - D Sales Forecast
Fig. 17 Alexion Pharmaceuticals SWOT